Browse Studies — Arctuva

Phase 3

A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 3…

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases

Estimated

~$10 – $8,750